The $63.8 Million Accounting Gain That Turned a Loss Into a Profit Headline

The $63.8 million number that made Microvast look profitable last quarter was never going to show up in a bank account.

Microvast Holdings (NASDAQ: MVST) reported GAAP net profit of $48.2 million for the first quarter of 2026. The headline looks like a company weathering headwinds while staying in the black. Strip away the profit, though, and the story changes entirely: $63.8 million of that number came from changes in the fair value of warrant liabilities and convertible loans — an accounting adjustment, not a dollar earned from selling batteries. The non-GAAP adjusted net loss for the same quarter was $14.6 million. Operating cash flow for the first half of the year swung from $44.3 million generated in 2025 to $33.3 million consumed in 2026.

The story works until this line. Then you have to ask who is paying for the difference between the margin targets management described and the margins the business is producing.

Microvast's stock price today — about $0.80 per share — is the cumulative receipt for that question. The company has been carved down through a sequence of disclosures that each peeled back a layer between the narrative and the cash register.

June 2025 was the first crack. A short-seller report from Grizzly Research alleged Microvast was overstating activity at its Chinese production facilities and inflating the economic value of its commercial partnerships. Grizzly cited Chinese government documents showing Microvast's main Huzhou subsidiary employed approximately 1,400 people — far below the 2,500-plus figure the company had described in prior filings — and pointed to partner companies like Gaussin (which entered compulsory liquidation) and eVersum (generating less than €7 million in revenue against prior projections of over €100 million in battery purchases). The stock fell roughly 10% that day. Management dismissed the report. The company did not reconcile the employee count or partner revenue figures.

August 2025, the second signal. Chief Financial Officer Pat Schultz — who had joined the company only three months earlier, in April — departed. The stock dropped another 9.9% on August 4, closing at $2.72. CFO turnover after 90 days is not fraud. It is a reason to check whether the person who was supposed to be reconciling the numbers found something that made staying difficult.

November 2025, the third. Microvast reported Q3 results and disclosed that the Huzhou Phase 3.2 expansion — previously described as coming online by Q4 2025 — would not begin production until Q1 2026. The timeline slip mattered because investors had been pricing the additional 2 GWh of modular capacity as a margin recovery lever. The stock fell 10% the next day.

Then came March 16, 2026, and the quarter where everything that had been deferred caught up at once.

Microvast reported fiscal year 2025 and Q4 results. Gross margin collapsed to approximately 1%, down from approximately 36% in the prior year, due to inventory impairment charges on specialized energy storage components. Revenue fell 15% year over year, attributed to "regulatory shifts in South Korea and delays in customer platform ramp-up" across Europe, the Middle East, and Africa. The stock price fell more than 34% the next day, closing at $1.52.

This sequence is the backbone of a securities class action lawsuit — captioned Graham v. Microvast Holdings, Inc., filed in the Southern District of Texas — which covers investors who purchased stock between April 1, 2025 and March 16, 2026. The complaint alleges that Microvast and its officers made materially false statements about margin targets, expansion timelines, and business prospects while failing to disclose inventory management problems, commercial vehicle rollout delays, and the inability to complete the Huzhou expansion as promised.

This is an allegation, not a finding. The case is at Level Four on the evidence ladder: a sourced complaint naming specific misrepresentations and omissions. It does not become Level Five until a court, the SEC, or Microvast itself establishes liability, orders a restatement, or settles with an admission.

Now follow the same dollar into the cash-flow statement.

Q1 2026 was the quarter where the GAAP profit and the operating reality diverged most dramatically. Revenue fell 48% year over year, to $60.6 million. Gross margin compressed from 36.9% to 31.6%. Non-GAAP adjusted EBITDA flipped from $28.5 million of profit to $5.5 million of loss. Management called it "strategic agility amid evolving geopolitical dynamics."

But the GAAP income statement showed $48.2 million of net profit. Where did that come from?

Warrant liabilities and convertible loans are hybrid securities that can swing wildly in fair value as the stock price moves. When Microvast's stock was trading higher in the class period — above $3 — the fair value of those obligations was elevated. As the stock tumbled, the fair value of the liabilities shrank, and the reduction flows through the income statement as a gain. It is a real accounting entry but not operating income. The company did not sell any more batteries to earn it. It simply watched a stock price collapse and booked the difference.

The non-GAAP adjusted net loss of $14.6 million strips that gain out. Adjusted EBITDA of negative $5.5 million strips it out along with interest, taxes, depreciation, and amortization. Those are the numbers that describe whether the battery business is making money at this utilization rate. The answer is no.

Q2 2026 provided a partial recovery but not a reversal of the trend. Revenue rose to $87.3 million — still down 4.5% year over year. Gross margin was 29.5%, down from 34.7% in Q2 2025. GAAP net loss narrowed to $12 million from a $106.1 million loss in the same quarter of 2025, but that improvement was almost entirely a function of the prior year being an outlier for warrant-related charges. Adjusted EBITDA was $3.6 million, down from $25.9 million. For the first half of 2026 combined, adjusted EBITDA swung from positive $54.4 million in 2025 to a small loss.

The cash flow reversal is the part that does not depend on definitions. Microvast used $33.3 million in operating cash flow during H1 2026, compared to generating $44.3 million in the same period the prior year. The company had $174 million in cash and restricted cash as of March 31, 2026, which is adequate runway for now. But every quarter of margin compression, capacity expansion, and negative operating cash flow eats into that cushion. Deloitte, Microvast's auditor, has reiterated a going concern warning — the formal accounting signal that the company's ability to continue operations is in doubt.

The governance overhang deepened in June 2026. Chief Accounting Officer Eric Garcia departed on May 27, and the shareholder rights firm Halper Sadeh LLC commenced an investigation into whether certain officers and directors breached their fiduciary duties. That is a separate proceeding from the Graham class action but points to the same fault line: whether the financial reporting during the class period was accurate.

Three CFOs and a CAO have turned over in roughly 18 months. Fariyal Khanbabi left in April 2025. Pat Schultz lasted three months. An interim CFO, Rodney Worthen, was followed by Eric Garcia as CAO, who departed in May 2026. Financial leadership instability is not evidence of fraud, but it is the kind of turbulence that makes it harder to pin down who was responsible for each set of numbers.

Here is the most plausible innocent explanation for what happened: Microvast is a capital-intensive battery company competing in a sector where European EV demand has softened, Asian regulatory shifts are disruptive, and OEM ramp-up timelines are inherently uncertain. Inventory impairment on specialized components is a real cost when product design cycles change or a customer delays a platform launch. The Huzhou expansion encountered construction and commissioning delays that are common in heavy industrial build-outs. Margin compression from lower utilization is a mechanical outcome of fixed costs spread across fewer units. Grizzly Research's short report, like all short reports, may have been more aggressive in its conclusions than its evidence warranted — and some of the partners it dismissed may still develop into material customers.

That explanation does not require fraud. But it also does not explain why the company described margin targets, expansion timelines, and customer traction with certainty that the underlying execution could not support. The benign story is that management was optimistic and wrong. The adverse story is that the statements crossed from optimism into misrepresentation. The difference between those two readings matters enormously — for the class action, for future capital raising, and for whether any recovery in the stock price is durable or another setup for disappointment.

Management's responses during the class period deserve their strongest form. CEO Yang Wu dismissed Grizzly's report publicly. The company has continued to report capacity expansion progress — Huzhou Phase 3.2 commissioning is now complete, with production targeted for late 2026 — and has pointed to European revenue growth, with Europe now accounting for 61% of quarterly revenue, up from 43% in the prior year. The Clarksville facility in Tennessee is being positioned for North American pack assembly by year-end 2026.

These are forward-looking commitments. They are credible as a business plan but not as a reconciliation of the past. They do not answer the question of whether margin targets and expansion timelines described during the class period had a reasonable basis at the time they were made. The company has not restated its prior results, has not admitted the class-action allegations, and has not yet filed a definitive response to the Graham complaint.

The shareholder invoice is written in the share price. From the peak of the class period, when the stock traded above $4.50, to the current level of approximately $0.80, the company's market capitalization has been reduced by roughly 80%. For an investor who bought at the average price during the class period, the loss is measured in tens of thousands of dollars for every few thousand shares held. The lead plaintiff deadline for the Graham class action is September 21, 2026.

Under three cases:

Resolved innocently. The statements had a reasonable basis at the time, market conditions changed, and the company's execution challenges are ordinary business risk. The class action is dismissed or settles for a nominal amount. The stock's recovery depends entirely on whether Huzhou Phase 3.2 reaches capacity, margins stabilize above cash-burn levels, and the European customer base deepens. At the current $0.80 price, the market has already priced in significant doubt.

Persistent but lawful. The statements were aggressively optimistic but not provably false. The company settles the class action for a meaningful amount — likely in the tens of millions given the class size and the magnitude of the price decline — without admitting wrongdoing. The cash payment further depletes the $174 million balance. The stock trades at a discount to its operational value until the next earnings cycle demonstrates that cash conversion is sustainable.

Materially misstated. The class action establishes that Microvast overstated capacity, overstated partner value, or failed to disclose inventory problems with the knowledge of management. The company faces restatement, additional litigation, potential SEC enforcement, and a going-concern crisis that Deloitte's warning already foreshadows. The $174 million in cash is insufficient to fund continued operations without dilutive equity issuance. At $0.80 per share, further dilution would compound existing losses for current shareholders.

The number is not proof. It is the door. The $63.8 million warrant gain that turned a $14.6 million loss into a $48.2 million profit is the hinge on which the entire Q1 2026 narrative turned. Without it, there is no GAAP profit headline. Without GAAP profit, the story of a resilient battery company navigating temporary headwinds collapses into something more honest: a capital-intensive business with contracting margins, negative operating cash flow, and a capacity build-out that keeps moving its completion date.

This case moves from Level Four to Level Three only if independent records — customer filings, customer revenue data, or Chinese government employment records — corroborate the complaint's allegations about overstated capacity and partner value. The next settling event is not the lead-plaintiff deadline. It is the discovery phase of the Graham litigation, when Microvast's internal documents about margin forecasting, expansion scheduling, and partner due diligence are subject to scrutiny by plaintiffs' counsel. Until then, the evidence supports a clear diagnosis: the profit was an accounting artifact, the cash was flowing out, and the governance smoke alarms were real. Whether that amounts to misrepresentation or aggressive optimism remains the question the filing room has not yet answered.